TVTX Latest Headlines

Analyst Reiterates Buy on Travere as Civorebrutinib Deal Expands Renal Franchise; $56 Price Target Maintained

at www.tipranks.com (Wed, 3-Jun 9:38 AM)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Elanco Animal Health (ELAN), AbSci (ABSI) and Travere Therapeutics (TVTX)

at www.tipranks.com (Wed, 3-Jun 8:01 AM)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Picard Medical, Inc. (PMI) and Travere Therapeutics (TVTX)

at www.tipranks.com (Wed, 3-Jun 7:50 AM)

Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

at www.tipranks.com (Wed, 3-Jun 7:43 AM)

Guggenheim Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

at www.tipranks.com (Wed, 3-Jun 7:28 AM)

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Gilead Sciences (GILD) and Celcuity (CELC)

at www.tipranks.com (Wed, 3-Jun 5:31 AM)

Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines

at seekingalpha.com (Tue, 2-Jun 8:07 AM)

Travere Licenses Civorebrutinib, Expands Kidney Disease Pipeline

at www.tipranks.com (Tue, 2-Jun 7:40 AM)

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Glaukos (GKOS)

at www.tipranks.com (Fri, 29-May 9:01 AM)

Travere’s $475 Million Convertible Notes Offering Signals Strategic Shift with 2032 Maturity and Repurchase Plan

Market Chameleon (Thu, 7-May 9:46 AM)

TVTX Rallies after FDA Grants Full Approval to FILSPARI, Expanding Treatment for Rare Kidney Disease

Market Chameleon (Tue, 14-Apr 10:29 AM)

FDA Approves FILSPARI for FSGS: Travere Therapeutics Achieves a First for Rare Kidney Disease

Market Chameleon (Tue, 14-Apr 7:29 AM)